Clinical significance of peripheral blood exosomal target protein expression in early screening and prognosis of patients with lung non-small cell carcinoma

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200061697

Enrollment

Unknown

Registered

2022-06-30

Start date

2022-06-30

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

Test Group:none

Control Group:none

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged > 18 years; 2. Newly diagnosed single primary lung adenocarcinoma that has not been treated; 3. No cardiovascular disease (systolic blood pressure < 180 mmHg or diastolic blood pressure < 110 mmHg), diabetes (fasting blood glucose < 7.0 mmol/L) and other underlying diseases; 4. Voluntarily sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. During pregnancy or breastfeeding; 2. Currently suffering from febrile illness; 3. Acute attack requiring drug treatment within 14 days before blood draw; 4. Those who have received organ transplantation or bone marrow stem cell transplantation; 5. Previous or current treatment for any cancer; 6. Blood transfusion within 30 days before study blood collection; 7. Those who are unable to cooperate in completing the survey due to reading and communication barriers.

Design outcomes

Primary

Measure	Time frame
Plasma exosome target protein expression;Tumor T lymphocytes infiltrate CD8 + tumor infiltrating lymphocyte;EGFR Gene;	—

Countries

China

Contacts

Public ContactDong Ming

Guangzhou Zhaorui Medical Biotechnology Co., Ltd.

DONG_MING@gzlab.ac.cn+86 18676711598

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026